Category Archives: "INforMS"

Genentech presenting new Ocrevus (Ocrelizumab) data at AAN Meeting
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and [...]
MSAA recognizes ten years of artwork from individuals with multiple sclerosis
CHERRY HILL, N.J., May 2, 2019 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to recognize ten years of [...]
FDA approves MAVENCLAD® (Cladribine) tablets
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's [...]
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Novartis receives FDA approval for MAYZENT (Siponimod)
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Dose-finding study for SAR442168 in relapsing multiple sclerosis
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]
BrainStorm announces first patient in phase 2 clinical trial progressive multiple sclerosis
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]
Depression, psychological distress symptoms affect multiple sclerosis patients’ quality of life
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM